Literature DB >> 16599646

Tailoring nicotine replacement therapy: rationale and potential approaches.

Jennifer B McClure1, Gary E Swan.   

Abstract

Nicotine replacement therapy (NRT) is an effective treatment for smoking cessation, but as with all such pharmacotherapies, the majority of smokers who use NRT products do not stop smoking or remain abstinent long term. Treatment outcome is affected by a range of individual-specific factors, as well as the pharmacokinetic profile of each NRT formulation. This has led to speculation that abstinence rates could be improved if NRT treatments were individually tailored to best match each individual's needs and preferences. There are also populations for whom special product and dosage considerations are warranted to maximise treatment safety.This paper reviews the rationale for NRT treatment, standard dose recommendations and recommendations for how to best match NRT treatment to the specific needs of individual smokers. We also review emerging evidence that genetic profiling may one day be a useful consideration for tailoring NRT treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16599646     DOI: 10.2165/00023210-200620040-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  92 in total

Review 1.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.

Authors:  H Yamazaki; K Inoue; M Hashimoto; T Shimada
Journal:  Arch Toxicol       Date:  1999-03       Impact factor: 5.153

Review 3.  Sex differences in nicotine effects and self-administration: review of human and animal evidence.

Authors:  K A Perkins; E Donny; A R Caggiula
Journal:  Nicotine Tob Res       Date:  1999-12       Impact factor: 4.244

4.  Female sex and oral contraceptive use accelerate nicotine metabolism.

Authors:  Neal L Benowitz; Christina N Lessov-Schlaggar; Gary E Swan; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

5.  Smoking cessation guidelines for health professionals: an update. Health Education Authority.

Authors:  R West; A McNeill; M Raw
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

6.  The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.

Authors:  A M Joseph; S M Norman; L H Ferry; A V Prochazka; E C Westman; B G Steele; S E Sherman; M Cleveland; D O Antonuccio; D O Antonnucio; N Hartman; P G McGovern
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

7.  Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Authors:  Elaine C Johnstone; Patricia L Yudkin; Kate Hey; Sarah J Roberts; Sarah J Welch; Michael F Murphy; Siân E Griffiths; Robert T Walton
Journal:  Pharmacogenetics       Date:  2004-02

Review 8.  Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans.

Authors:  J R Cashman; S B Park; C E Berkman; L E Cashman
Journal:  Chem Biol Interact       Date:  1995-04-28       Impact factor: 5.192

9.  Treatment of adolescent smokers with the nicotine patch.

Authors:  Karen Hanson; Sharon Allen; Sue Jensen; Dorothy Hatsukami
Journal:  Nicotine Tob Res       Date:  2003-08       Impact factor: 4.244

10.  Recruiting pregnant smokers for a placebo-randomised controlled trial of nicotine replacement therapy.

Authors:  Tim Coleman; Marilyn Antoniak; John Britton; Jim Thornton; Sarah Lewis; Kim Watts
Journal:  BMC Health Serv Res       Date:  2004-11-01       Impact factor: 2.655

View more
  16 in total

1.  Nicotine reinforcement in never-smokers.

Authors:  Angela N Duke; Matthew W Johnson; Chad J Reissig; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2015-09-08       Impact factor: 4.530

2.  Temporal Trends of Psychosociobehavioral Factors Underlying Tobacco Use: A Semi-Automated Exploratory Analysis of Peer-to-Peer Communication in a Health-Related Online Community.

Authors:  Vishnupriya Sridharan; Trevor Cohen; Nathan Cobb; Sahiti Myneni
Journal:  Stud Health Technol Inform       Date:  2017

3.  Adherence to and consumption of nicotine replacement therapy and the relationship with abstinence within a smoking cessation trial in primary care.

Authors:  Gareth J Hollands; Stephen Sutton; Máirtín S McDermott; Theresa M Marteau; Paul Aveyard
Journal:  Nicotine Tob Res       Date:  2013-02-19       Impact factor: 4.244

Review 4.  Pharmacogenetics and smoking cessation with nicotine replacement therapy.

Authors:  Riju Ray; Robert A Schnoll; Caryn Lerman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  Tobacco use and cessation for cancer survivors: an overview for clinicians.

Authors:  Maher Karam-Hage; Paul M Cinciripini; Ellen R Gritz
Journal:  CA Cancer J Clin       Date:  2014-05-09       Impact factor: 508.702

6.  Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence.

Authors:  Amy C Janes; Blaise deB Frederick; Sarah Richardt; Caitlin Burbridge; Emilio Merlo-Pich; Perry F Renshaw; A Eden Evins; Maurizio Fava; Marc J Kaufman
Journal:  Exp Clin Psychopharmacol       Date:  2009-12       Impact factor: 3.157

Review 7.  Update on pharmacologic and nonpharmacologic therapies for smoking cessation.

Authors:  Jason Schmelzle; Walter W Rosser; Richard Birtwhistle
Journal:  Can Fam Physician       Date:  2008-07       Impact factor: 3.275

8.  Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.

Authors:  Kenneth A Perkins; Caryn Lerman; Melissa Mercincavage; Carolyn A Fonte; Jessica L Briski
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-15       Impact factor: 4.254

Review 9.  Genetics of nicotine dependence and pharmacotherapy.

Authors:  Christina N Lessov-Schlaggar; Michele L Pergadia; Taline V Khroyan; Gary E Swan
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

Review 10.  Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.

Authors:  Rafael Laniado-Laborín
Journal:  Int J Environ Res Public Health       Date:  2009-01-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.